MX9302195A - Derivados de indol, procedimiento para su reparacion y composicion farmaceutica que los comprende. - Google Patents

Derivados de indol, procedimiento para su reparacion y composicion farmaceutica que los comprende.

Info

Publication number
MX9302195A
MX9302195A MX9302195A MX9302195A MX9302195A MX 9302195 A MX9302195 A MX 9302195A MX 9302195 A MX9302195 A MX 9302195A MX 9302195 A MX9302195 A MX 9302195A MX 9302195 A MX9302195 A MX 9302195A
Authority
MX
Mexico
Prior art keywords
derivatives
indol
repair
procedure
pharmaceutical composition
Prior art date
Application number
MX9302195A
Other languages
English (en)
Spanish (es)
Inventor
Alfredo Cugola
Giovanni Gavirachi
Simone Giacobre
Original Assignee
Glaxo Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Spa filed Critical Glaxo Spa
Publication of MX9302195A publication Critical patent/MX9302195A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
MX9302195A 1992-04-16 1993-04-15 Derivados de indol, procedimiento para su reparacion y composicion farmaceutica que los comprende. MX9302195A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929208492A GB9208492D0 (en) 1992-04-16 1992-04-16 Heterocyclic compounds

Publications (1)

Publication Number Publication Date
MX9302195A true MX9302195A (es) 1994-03-31

Family

ID=10714220

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9302195A MX9302195A (es) 1992-04-16 1993-04-15 Derivados de indol, procedimiento para su reparacion y composicion farmaceutica que los comprende.

Country Status (41)

Country Link
US (4) US5374648A (enExample)
EP (1) EP0568136A1 (enExample)
JP (2) JPH0649027A (enExample)
KR (1) KR100264114B1 (enExample)
CN (1) CN1042331C (enExample)
AP (1) AP480A (enExample)
AT (1) AT403917B (enExample)
AU (1) AU666927B2 (enExample)
BE (1) BE1006343A5 (enExample)
BG (1) BG62136B1 (enExample)
BR (1) BR1100323A (enExample)
CA (3) CA2094073A1 (enExample)
CH (1) CH685630A5 (enExample)
CY (1) CY2038B1 (enExample)
CZ (1) CZ285799B6 (enExample)
DK (1) DK169890B1 (enExample)
ES (1) ES2105924B1 (enExample)
FI (1) FI106198B (enExample)
FR (1) FR2690919B1 (enExample)
GB (2) GB9208492D0 (enExample)
GE (1) GEP19991704B (enExample)
GR (1) GR1001619B (enExample)
HK (1) HK95797A (enExample)
HU (2) HU217964B (enExample)
IL (1) IL105412A (enExample)
IS (1) IS3994A (enExample)
IT (1) IT1265325B1 (enExample)
LU (1) LU88248A1 (enExample)
MX (1) MX9302195A (enExample)
MY (1) MY112232A (enExample)
NO (1) NO301879B1 (enExample)
NZ (1) NZ247413A (enExample)
OA (1) OA10103A (enExample)
PL (1) PL176451B1 (enExample)
RO (1) RO113242B1 (enExample)
RU (1) RU2129544C1 (enExample)
SE (1) SE504336C2 (enExample)
SK (1) SK281941B6 (enExample)
TW (1) TW224457B (enExample)
WO (1) WO1993021153A1 (enExample)
ZA (1) ZA932642B (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9304500D0 (en) * 1993-03-05 1993-04-21 Glaxo Spa Heterocyclic compounds
US5519048A (en) * 1993-05-27 1996-05-21 Merrell Pharmaceuticals Inc. 3-(indol-3-yl)-propenoic acid derivatives and pharmaceutical compositions thereof
CN1051302C (zh) * 1993-05-27 2000-04-12 默里尔药物公司 3－(吲哚－3－基)丙烯酸衍生物及其用作nmda拮抗剂
GB9319243D0 (en) * 1993-09-17 1993-11-03 Glaxo Spa Heterocyclic compounds
GB9321221D0 (en) * 1993-10-14 1993-12-01 Glaxo Spa Heterocyclic compounds
TW280819B (enExample) * 1993-11-17 1996-07-11 Sumitomo Pharma
US5563157B1 (en) * 1994-10-31 1999-02-02 Hoecst Marion Roussel Inc Heterocycle substituted propenoic acid derivatives and pharmaceutical compositions thereof
GB9502695D0 (en) * 1995-02-11 1995-03-29 Glaxo Spa Pharmaceutical composition
GB9504361D0 (en) * 1995-03-04 1995-04-26 Glaxo Spa Heterocyclic compounds
AU4416197A (en) * 1996-09-17 1998-04-14 Regents Of The University Of California, The Positive ampa receptor modulation to enhance brain neurotrophic factor expression
IL129187A0 (en) * 1996-09-30 2000-02-17 Hoechst Marion Roussel Inc NMDA (N-methyl-D-aspartate) antagonists
US5922752A (en) * 1997-06-11 1999-07-13 Hoechst Marion Roussell, Inc. NMDA (n-methyl-d-aspartate) antagonists
PT2198858E (pt) * 1998-03-26 2011-09-01 Astellas Pharma Inc Composição farmacêutica de libertação constante que contém um macrólido como o tacrolimus
HK1054231A1 (en) * 2000-07-31 2003-11-21 Dainippon Sumitomo Pharma Co., Ltd. Dementia remedies containing 2-aryl-8-oxodihydropurine derivatives as the active ingredient
WO2003039540A2 (en) * 2001-11-09 2003-05-15 Sepracor Inc. D-amino acid oxidase inhibitors for learning and memory
CA2468544A1 (en) * 2001-12-10 2003-06-19 Amgen Inc. Vanilloid receptor ligands
PA8579701A1 (es) * 2002-08-23 2005-05-24 Pfizer Prod Inc Profarmaco inhibidor de beta-lactamasa
DE10306202A1 (de) * 2003-02-13 2004-08-26 Grünenthal GmbH Arzneimittel enthaltend substituierte 2-Aryl-Aminoessigsäure-Verbindungen und/oder substituierte 2-Heteroaryl-Aminoessigsäure-Verbindungen
EP1636240A1 (en) * 2003-06-05 2006-03-22 Pfizer Products Inc. Beta-lactamase inhibitor prodrug
RU2247563C1 (ru) * 2003-06-16 2005-03-10 Пятигорская государственная фармацевтическая академия Способ получения твердой лекарственной формы, содержащей глюкозамина гидрохлорид
US7671072B2 (en) * 2003-11-26 2010-03-02 Pfizer Inc. Aminopyrazole derivatives as GSK-3 inhibitors
CN1922149A (zh) * 2003-12-29 2007-02-28 塞普拉科公司 吡咯和吡唑daao抑制剂
RU2281755C2 (ru) * 2004-04-19 2006-08-20 Пятигорская государственная фармацевтическая академия Композиция - лекарственная форма противоартрозного средства глюкозамина гидрохлорида для ректального применения
US20060002999A1 (en) * 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
CA2614282A1 (en) 2005-07-06 2007-01-11 Sepracor Inc. Combinations of eszopiclone and trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders
EP1976513B1 (en) 2006-01-06 2016-08-24 Sunovion Pharmaceuticals Inc. Cycloalkylamines as monoamine reuptake inhibitors
KR101381768B1 (ko) * 2006-01-06 2014-04-07 선오비온 파마슈티컬스 인코포레이티드 테트랄론-기재 모노아민 재흡수 저해제
PT2816024T (pt) 2006-03-31 2017-10-20 Sunovion Pharmaceuticals Inc Aminas quirais
US7579370B2 (en) * 2006-06-30 2009-08-25 Sepracor Inc. Fused heterocycles
US7884124B2 (en) * 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
US20080082066A1 (en) * 2006-10-02 2008-04-03 Weyerhaeuser Co. Crosslinked carboxyalkyl cellulose fibers having non-permanent and temporary crosslinks
EP1942104A1 (en) 2006-12-20 2008-07-09 sanofi-aventis Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals
JP2010516697A (ja) * 2007-01-18 2010-05-20 セプラコール インク． Ｄ−アミノ酸オキシダーゼ阻害剤
US7902252B2 (en) * 2007-01-18 2011-03-08 Sepracor, Inc. Inhibitors of D-amino acid oxidase
WO2008151156A1 (en) 2007-05-31 2008-12-11 Sepracor Inc. Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors
US20090247644A1 (en) * 2008-03-28 2009-10-01 Forest Laboratories Holdings Limited Memantine formulations
US20100120740A1 (en) * 2008-08-07 2010-05-13 Sepracor Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
US20110319463A1 (en) * 2009-03-10 2011-12-29 Saten Pharamaceuticals Co., Ltd. Preventive or therapeutic agents for optic nerve disorders comprising 4,6-dichloro-1h-indole-2-carboxylic acid derivatives or salts thereof as active ingredients
US20110034434A1 (en) * 2009-08-07 2011-02-10 Sepracor Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
CA2946153C (en) 2014-04-30 2022-06-14 Yufeng Jane Tseng Use of known compounds as d-amino acid oxidase inhibitors
CA3036250C (en) 2016-09-14 2023-09-26 Yufeng Jane Tseng Novel substituted benzimidazole derivatives as d-amino acid oxidase (daao) inhibitors
CN110996948A (zh) 2017-06-12 2020-04-10 格莱泰施有限责任公司 用nmda拮抗剂和d2/5ht2a或选择性5ht2a拮抗剂治疗抑郁症
CN112707874A (zh) * 2020-12-29 2021-04-27 广东中科药物研究有限公司 一种抗病毒化合物及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3010971A (en) * 1960-08-04 1961-11-28 Smith Kline French Lab Cyclopropylamine derivatives and processes for their preparation
DK500285A (da) * 1984-11-02 1986-05-03 Glaxo Group Ltd Cephalosporinantibiotika
US4960786A (en) * 1989-04-24 1990-10-02 Merrell Dow Pharmaceuticals Inc. Excitatory amino acid antagonists
PT93943A (pt) * 1989-05-05 1991-02-08 Searle & Co Processo para a preparacao de composicoes contendo compostos indole-2-carboxilato para tratamento de perturbacoes do snc
EP0539503B1 (en) * 1990-07-16 1996-04-03 Merrell Dow Pharmaceuticals Inc. Excitatory amino acid antagonists
US5284862A (en) * 1991-03-18 1994-02-08 Warner-Lambert Company Derivatives of 2-carboxyindoles having pharmaceutical activity
US5145845A (en) * 1991-05-14 1992-09-08 Warner-Lambert Co. Substituted 2-carboxylindoles having pharmaceutical activity

Also Published As

Publication number Publication date
FR2690919A1 (fr) 1993-11-12
ES2105924A1 (es) 1997-10-16
ZA932642B (en) 1994-01-10
IL105412A (en) 1998-02-22
HK95797A (en) 1997-08-08
HUT70526A (en) 1995-10-30
SE504336C2 (sv) 1997-01-13
US5374648A (en) 1994-12-20
GB2266091B (en) 1995-08-09
NO943913L (no) 1994-12-14
SK124194A3 (en) 1995-05-10
IL105412A0 (en) 1993-08-18
JPH0649027A (ja) 1994-02-22
NO301879B1 (no) 1997-12-22
SE9301241D0 (sv) 1993-04-15
AP480A (en) 1996-03-22
GB9307808D0 (en) 1993-06-02
IT1265325B1 (it) 1996-10-31
IS3994A (is) 1993-10-17
OA10103A (en) 1996-12-18
AT403917B (de) 1998-06-25
EP0568136A1 (en) 1993-11-03
ES2105924B1 (es) 1998-07-01
FR2690919B1 (fr) 1995-05-05
CA2094076A1 (en) 1993-10-17
BE1006343A5 (fr) 1994-07-26
BG62136B1 (bg) 1999-03-31
CH685630A5 (fr) 1995-08-31
ITRM930236A1 (it) 1994-10-15
HU217964B (hu) 2000-05-28
CA2094075A1 (en) 1993-10-17
ATA75293A (de) 1997-11-15
DK169890B1 (da) 1995-03-27
US5373018A (en) 1994-12-13
AP9300524A0 (en) 1993-04-30
TW224457B (enExample) 1994-06-01
BG99111A (bg) 1995-05-31
GB9208492D0 (en) 1992-06-03
RU94045915A (ru) 1996-09-10
LU88248A1 (fr) 1994-03-01
CY2038B1 (en) 1998-04-30
FI944800A0 (fi) 1994-10-12
JPH07505407A (ja) 1995-06-15
WO1993021153A1 (en) 1993-10-28
CA2094073A1 (en) 1993-10-17
DK43193A (da) 1993-10-17
CZ254394A3 (en) 1995-07-12
GEP19991704B (en) 1999-08-05
FI106198B (fi) 2000-12-15
GB2266091A (en) 1993-10-20
DK43193D0 (da) 1993-04-15
BR1100323A (pt) 2000-06-27
SK281941B6 (sk) 2001-09-11
KR100264114B1 (ko) 2000-11-01
HU211826A9 (en) 1995-12-28
CN1085212A (zh) 1994-04-13
CN1042331C (zh) 1999-03-03
AU666927B2 (en) 1996-02-29
FI944800L (fi) 1994-10-12
NZ247413A (en) 1995-12-21
PL176451B1 (pl) 1999-05-31
HU9402975D0 (en) 1995-02-28
AU3692393A (en) 1993-10-21
MY112232A (en) 2001-05-31
RO113242B1 (ro) 1998-05-29
US5374649A (en) 1994-12-20
GR1001619B (el) 1994-07-29
NO943913D0 (no) 1994-10-14
US5510367A (en) 1996-04-23
SE9301241L (sv) 1993-10-17
ITRM930236A0 (it) 1993-04-15
RU2129544C1 (ru) 1999-04-27
CZ285799B6 (cs) 1999-11-17

Similar Documents

Publication Publication Date Title
MX9300261A (es) Derivados de 1,5-benzodiacepina, proceso para su preparacion y composicion farmaceutica que los contiene.
ES2144192T3 (es) Nuevos derivados de 1-fenil-2-dimetil-amino-metil-ciclohexan-1-ol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
MX9400175A (es) Derivados de fenil tri-substituidos y proceso para su preparacion.
ECSP941104A (es) Derivados de 2,6 diaminopurina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
MX9307654A (es) Derivados de amina, proceso para su preparacion y composicion farmaceutica que los contiene.
MX9400166A (es) Microesferas de proteina vegetal, hidrolizada, modificada y metodos para su preparacion y su uso.
SV1998000029A (es) Compuestos de pirazina ref. pg3186
ES2059789T3 (es) Esteroides sustituidos con acido fosfinico como inhibidores de la esteroide-5 alfa-reductasa.
HN1998000157A (es) Agonistas de prostaglandinas
MX19448A (es) Procedimiento para la prreparacion de compuestos antagonistas de los receptores de aminoacidos excitadores; compuestos obtenidos y composicion farmaceutica que los incluye.
ES2191320T3 (es) Derivados de piperazina y su uso como agentes anti-inflamatorios.
MX9301129A (es) Nuevas ciclosporinas y composiciones farmaceuticas que las contienen.
ES2051678T1 (es) Derivados de 5-oxo-l-prolina y uso farmaceutico de los mismos.
ES2044870T3 (es) Un procedimiento para la preparacion de nuevos agentes antihipertensivos.
UY24986A1 (es) Compuestos
MX9301197A (es) Derivados de indol.
MX9201356A (es) Derivados de piperidina, procedimiento para su preparacion y composicion farmaceutica que los contiene.
ES2178055T3 (es) Derivados aminicos substituidos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
TR199801861T2 (xx) Farmas�tik olarak yararl� bile�imler.
ECSP941120A (es) Derivados de 1,5 benzodiazepina
HUT67237A (en) Excitatory amino acid antagonists indole derivatives, their preparation and pharmaceutical compositions comprising them
AR002017A1 (es) Derivados de fenil-4-tiazoles substituidos, procedimiento para su preparacion, composiciones farmaceuticas que los contienen y derivados defenil-4-tiazoles substituidos empleados en dicho procedimiento.
AR002704A1 (es) 2-(2-n-alcoxifenil)-purin-6-onas 9-sustituidas, procedimiento para su preparacion, composiciones farmaceuticas que las contienen y su uso parapreparar composiciones farmaceuticas.
MX9704034A (es) Derivados y composiciones de 1,1-dioxido de 2-arilcarboniloximetil-1,2,5-tiadiazolidin-3-ona substituido y metodo de uso.
CR6398A (es) Antagonistas de 5ht1 para terapia antidepresiva

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees